Dry eye drug combo safety trial pulled before it started
NCT ID NCT07111013
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to check the long-term safety of a new eye drop that combines two active ingredients (lifitegrast and perfluorohexyloctane) for people with dry eye disease. It was a follow-up for people who had already completed an earlier study. However, the trial was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lifitegrast and perfluorohexyloctane eye drops
- What this could lead to
- If successful, this could confirm a safe long-term treatment option for dry eye disease.
- What could go wrong
- The trial was withdrawn before enrolling anyone, so no data was collected. The combination's long-term safety remains unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Dry eye gel may sharpen cataract surgery results
- New eye drops could bring relief to millions with chronic dry eye
- Could stem cell eye drops soothe dry eyes?
- Second plug may boost dry eye comfort
- New AI reads eye scans to diagnose dry eye instantly
- Popular diabetes drugs may ease dry eye, study suggests